Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance
Open accessAbstract
Abstract Summary: The clinical success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Two reports in this issue of Cancer Discovery uncover additional mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment. These findings pave the way for clinical testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic. Cancer Discov; 2(10); 872–5. ©2012 AACR. Commentary on Ercan et al., p. 934. Commentary on Takezawa et al., p. 922.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The most common mechanism of acquired resistance, occurring in 49%-60%, is the T790M mutation in exon 20.
“The most common (49%-60%) mechanism of acquired resistance is the acquisition of a single recurrent missense mutation within exon 20, the T790M mutation [119, 120].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works
Self-citationNew driver mutations in non-small-cell lung cancer
Pao, W. J., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,172 · see citing works
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961 · see citing works
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 833 · see citing works
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710 · see citing works
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294 · see citing works
Ramalingam, S. S., Blackhall, F. H., Krzakowski, M. J., Barrios, C. H., Park, K., Bover, I., Heo, D. S., Rosell, R., Talbot, D. C., Frank, R. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9433 · Cited by 263 · see citing works
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
Cohenuram, M. K., & Saif, M. W. (2006) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32800feecb · Cited by 131 · see citing works
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 129 · see citing works
Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
Workman, P., & Clarke, P. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.020 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631 · see citing works
Genetics and biomarkers in personalisation of lung cancer treatment
Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 304 · see citing works
Eno, M. S., Brubaker, J. D., Campbell, J. E., Savi, C. D., Guzi, T. J., Williams, B. D., Wilson, D. P., Wilson, K. J., Brooijmans, N., Kim, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00704 · Cited by 194 · see citing works
Engelhardt, H., Böse, D., Petronczki, M. P., Scharn, D., Bader, G., Baum, A., Bergner, A., Chong, E., Döbel, S., Egger, G., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01169 · Cited by 165 · see citing works
Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 135 · see citing works
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 123 · see citing works
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 119 · see citing works
Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors
Amrhein, J. A., Knapp, S., & Hanke, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00217 · Cited by 109 · see citing works
Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I. S., Plotnick, D. O., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2811 · Cited by 101 · see citing works
Juchum, M., Günther, M., Döring, E., Sievers‐Engler, A., Lämmerhofer, M., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00178 · Cited by 84 · see citing works
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 65 · see citing works
Addressing the unmet need in lung cancer: The potential of immuno-oncology
Scagliotti, G. V., Bironzo, P., & Vansteenkiste, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.001 · Cited by 40 · see citing works
Harwardt, M.-L. I. E., Schröder, M. S., Li, Y.-Q., Malkusch, S., Freund, P., Gupta, S., Janjić, N., Strauss, S., Jungmann, R., Dietz, M. S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082803 · Cited by 41 · see citing works
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41 · see citing works
Amrhein, J. A., Beyett, T. S., Feng, W. W., Krämer, A., Weckesser, J., Schaeffner, I. K., Rana, J. K., Janne, P. A., Eck, M. J., Knapp, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01041 · Cited by 36 · see citing works
Wang, Y., Zhang, T., Guo, L., Ren, T., & Yang, Y. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.11.001 · Cited by 29 · see citing works
Howell, M., Green, R. J., Khalil, R., Foran, E. A., Quarni, W., Nair, R. R., Stevens, S. M., Grinchuk, A., Hanna, A., Mohapatra, S. S., et al. (2019) · FASEB BioAdvances · doi:10.1096/fba.2019-00081 · Cited by 25 · see citing works
Tanaka, H., Sakagami, H., Kaneko, N., Konagai, S., Yamamoto, H., Matsuya, T., Yuri, M., Yamanaka, Y., Mori, M., Takeuchi, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0976 · Cited by 18 · see citing works
Chung, K., Huang, Y., Chen, Y., Juan, Y., Hsu, C., Nakahira, K., Huang, Y., Lin, M., Wu, S., Shih, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12843 · Cited by 18 · see citing works
Liu, B., Gao, F., Zhao, H., Yuan, S., Peng, X., Zhang, P., Wang, J., Zhang, T., Duan, M., & Guo, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115590 · Cited by 18 · see citing works
Larsen, M. E., Lyu, H., & Liu, B. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2022.12.001 · Cited by 17 · see citing works
Zhou, H., Fu, H., Shao, X., & Cai, W. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01636 · Cited by 17 · see citing works
Ma, Y., Liu, F., Zhang, Y., Chen, Q., Chen, Z., Liu, Q., Huang, Y., Yang, Y., Fang, W., Xi, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024755 · Cited by 15 · see citing works
Kim, T. Y., Ji, E. S., Lee, J. Y., Kim, J. Y., Yoo, J. S., Szász, A. M., Döme, B., Marko‐Varga, G., & Kwon, H. J. (2020) · Cancers · doi:10.3390/cancers12092613 · Cited by 11 · see citing works
Mountzios, G., Koumarianou, A. A., Bokas, A., Mavroudis, D., Samantas, E., Fergadis, E., Linardou, H., Katsaounis, P., Athanasiadis, E., Karamouzis, M. V., et al. (2021) · Cancers · doi:10.3390/cancers13133172 · Cited by 10 · see citing works
Kageji, H., Momose, T., Nagamoto, Y., Togashi, N., Yasumatsu, I., Nishikawa, Y., Kihara, K., Hiramoto, K., Minami, M., Kasanuki, N., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129575 · Cited by 9 · see citing works
Song, X., Wu, Y., Xiao-juan, Q., & Jiang, B. (2023) · MedComm – Oncology · doi:10.1002/mog2.50 · Cited by 8 · see citing works
Igawa, H., Könst, Z. A., Therrien, É., Shelley, M. Y., Koldsø, H., Bos, P. H., Negri, A., Verras, A., Guo, J., Dahlgren, M. K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01405 · Cited by 8 · see citing works
EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools
Howell, M., Green, R. J., Cianne, J., Dayhoff, G. W., Uversky, V. N., Mohapatra, S. S., & Mohapatra, S. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2153269 · Cited by 6 · see citing works
Tyson, D. R., & Quaranta, V. (2013) · Personalized Medicine · doi:10.2217/pme.13.6 · Cited by 6 · see citing works
Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC
Wang, T., Wang, Y., Lu, J., Chen, J., Wang, L., Ouyang, Z., Ouyang, W., Hu, C., Weng, J., & Zhang, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107714 · Cited by 4 · see citing works
Li, F., Ye, P., Cai, P., Dong, D., Zhang, Y., Yang, Y., & Sun, X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262822 · Cited by 3 · see citing works
Chen, V. C., Iwama, E., Kim, I., & Giaccone, G. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.032 · Cited by 3 · see citing works
Choi, C., & Lee, J. C. (2012) · Journal of Lung Cancer · doi:10.6058/jlc.2012.11.2.59 · Cited by 2 · see citing works
Mountzios, G., Lampaki, S., Koliou, G.-A., Vozikis, A., Kontogiorgos, I., Papantoniou, P., Koufaki, M.-I., Res, E., Boutis, A. L., Christopoulou, A. N., et al. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s318007 · Cited by 2 · see citing works
Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I. S., Plotnick, D. O., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., et al. (2023) · doi:10.1158/0008-5472.c.6512902.v1
- Authors
- Blakely, C. M., & Bivona, T. G.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Bivona, Trever G.
- Venue
- Cancer Discovery
- Published
- 2012-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 872-875
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC3475614
- OpenAlex
- W1982506332
- Cited by
- 39
- References
- 13
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 2 · 2013: 4 · 2012: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (R01CA169338, DP2CA174497, K08CA154787)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibitors, lung cancer, EGFR mutation, treatment resistance, EGFR kinase inhibitors, resistance mechanisms, combination therapy, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Humans, Lung Neoplasms, Mutation, Quinazolines, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Class I Phosphatidylinositol 3-Kinases, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
